ImaBiotech website in English


  • ASMS 2017

    Come and meet Rima Ait-Belkacem and Jonathan Stauber to discover all our capabilities. June 4- 8, 2017, in (...)

    Read more
  • Webinar on Immuno-Oncology by Rima AIT-BELKACEM, PhD

    The webinar titled “Immuno-Oncology: Tryptophan-Kynurenine Microenvironment Tumor Metabolites Pathway Highlighted by (...)

    Read more
See all news


In just a few days, test compound distribution in xenograft tissues without labeled compounds.

ImaBiotech quantitative provides MALDI Imaging Mass Spectrometry services unmatched by any other classical technique: quantitative label-free drug and biomarker distribution in oncology with high accuracy up to 20µm resolution.

Traditional drug pharmacokinetics and distribution with dissection can now be advantageously replaced by MALDI Imaging Mass Spectrometry, which offers accurate localization and quantitation of parent drugs and metabolites.

Figure : Images of Doxorubicin localization in tumor

Verbatim Oncology MSI

In Oncology, we can study :

Target Engagement


Toxicity effects

Decrease R&D costs and Increase speed of drug discovery
  • Identify the drug distribution in the heterogeneity of the tumors
  • Study the distribution and quantify within a molecular or biochemical pathway (ex. ovarian cancer or brain tumor)

Drug distribution and quantification
  • High resolution drug and metabolites imaging at 20µm
  • Molecule distribution in whole body, tumor and other target regions
  • Quantify drug and metabolites in whole body and specific organs
  • Combined with Biomarker imaging (Onco-metabolites)
  • Unknown metabolite research and identification

Development phases
  • Screening drug distribution
  • Lead optimization
  • Toxicity studies

  • Lung cancer (small cells)
  • Brain cancer
  • Colon cancer
  • Prostate cancer

Xenograft models
  • Glioblastoma
  • Lymphoma